MF
Michael Flax, D.D.S., M.S., P.A.
Chairman, Chief Executive Officer, Chief Financial Officer
Nutra PharmaNutra Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Alpha-Cobratoxin (Pharmaceutical) | Multiple Sclerosis (MS) | Preclinical |
| Modified Elapid Venoms (e.g., RPI-MN, RPI-78) | Bacterial, Viral, Parasitic Infections | Preclinical |
| Nyloxin® / Nyloxin Extra Strength® | Moderate to Severe Pain | Marketed |
| Pet Pain-Away | Pain in Dogs and Cats | Marketed |
| Equine Pain-Away | Pain and Inflammation in Horses | Marketed |